ISSN: 2684-1266
+44-77-2385-9429
Department Clinical Research, Beverly Hills Cancer Center, Beverly Hills, CA, USA
Case Series
Early use of Next Generation Sequencing Provided Alternative Treatment Options to 32.24% Cancer Patients (Avoiding or Delaying Chemotherapy): Retrospective Study in Solid Tumors at Beverly Hills Cancer Center
Author(s): Nathan Gabayan*, Ali Muhammad and Afshin Eli Gabayan
Our providers’ continuous efforts to obtain Next-generation sequencing for their cancer patients as early as possible
followed by matched therapy has provided new therapeutic options to our solid tumors patients. We report our
experience here with this approach in everyday clinical practice at the Beverly Hills Cancer Center along with our
robust clinical research program. This retrospective study included 95 solid tumor patients who were genotyped with
the FDA-approved Guardant360 CDx that provides comprehensive genomic results from a blood draw in seven days
X. Our oncologists use it on regular basis for tumor mutation profiling, also known as Comprehensive Genomic
Profiling (CGP), across all solid cancers and also as a companion diagnostic to identify non-small cell lung cancer
patients who may benefit from treatment with Tagrisso® (osimert.. View More»